X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
QRL-201 is a first-in-class precision therapeutic product candidate aiming to restore STATHMIN-2 (STMN2) expression in ALS patients. ANQUR is the first-ever study to evaluate a therapy that rescues STMN2 expression in ALS patients.
Lead Product(s): QRL-201
Therapeutic Area: Neurology Product Name: QRL-201
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
The proceeds from the financing will fund clinical development of QRL-201 and QRL-101, QurAlis's lead product candidates in ALS. QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients.
Lead Product(s): QRL-201
Therapeutic Area: Neurology Product Name: QRL-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: EQT Life Sciences
Deal Size: $88.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 09, 2023
Details:
QRL-101 a first-in-class selective Kv7.2/7.3 ion channel opener for the treatment of ALS that aims to reduce hyperexcitability-induced neurodegeneration. Drug dosing in Phase 1 clinical trial has been initiated.
Lead Product(s): QRL-101
Therapeutic Area: Neurology Product Name: QRL-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
QRL-201 is a first-in-class molecule that rescues STATHMIN-2, a well-known protein important for neural repair and axonal stability, the expression of which is significantly decreased in the majority of ALS patients.
Lead Product(s): QRL-201
Therapeutic Area: Neurology Product Name: QRL-201
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
QRL-101 (QRA-244) is QurAlis’ lead drug candidate intended to treat motor neuron hyperexcitability-induced disease progression in ALS patients, which is estimated to be up to 50% of all ALS cases.
Lead Product(s): QRA-244
Therapeutic Area: Neurology Product Name: QRA-244
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The poster presentation showed that QRA-244 has comparable effects to retigabine (ezogabine) at up to 20-fold lower concentration in motor neurons differentiated from patient-derived iPSCs as measured by an all-optical electrophysiology experiment.
Lead Product(s): QRA-244
Therapeutic Area: Neurology Product Name: QRA-244
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Poster titled "QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients " wail be presented MNDA 31st International Symposium on ALS/MND.
Lead Product(s): QRA-244
Therapeutic Area: Neurology Product Name: QRA-244
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
Company has penned a preclinical pact with Eli Lilly to deepen its ALS pipeline, in-licensing an undisclosed number of preclinical compounds with “disease modifying potential” in ALS by preventing disease-induced neuronal excitotoxicity.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 01, 2020
Details:
QurAlis intends to use this funding to support the development of new therapies for ALS and genetically related frontotemporal dementia (FTD), neurodegenerative diseases for which there is currently no cure.
Lead Product(s): Stem cell therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Polaris Partners
Deal Size: $42.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
